Random42 is one of the largest global medical animation producers. Animation is increasingly seen as a critical component of the marketing programme surrounding new drug development as well as having wider corporate uses.

DC Advisory (DC) were engaged by Graphite Capital (Graphite) in May 2017 to provide M&A advice in relation to the acquisition of Random42.

DC assisted in valuation guidance, assessment of market dynamics and potential exit options for Random42.

On 21 July 2017, Graphite announced the acquisition of Random42 for an undisclosed consideration.

With Graphite’s support, Random42 will focus on increasing its market share, building on its expertise and strong track record.  It will look to increase its geographic coverage further by expanding in Europe and the Far East while continuing to grow its core North American sales. The company will also explore opportunities in new markets such as educational materials, corporate promotions, animal health, over-the-counter drugs and medical devices.

We greatly valued DC Advisory’s strategic insight, process leadership and strong M&A execution capabilities which were critical to completing the transaction within a short timeframe.

Humphrey Baker
Partner at Graphite Capital

We are delighted to have worked with Graphite on its investment in Random42. Ben and his colleagues have built the business into a leader in a high-growth market, and Graphite will be an ideal partner to take Random42 to the next level.

David Sanders
Executive Director at DC Advisory